$0.00
$5.20
bear $0.00
base $0.20
bull $5.20
margin of safety $2.50
market price* $27.24
Business condition attached to the margin of safety
Operating cash flow less equipment spending, after counting stock compensation as a cost, at roughly half of today's level (about $65 million a year or less) while trailing-twelve-month revenue passes $150 million.
WHAT THE BUSINESS IS. Kestra Medical Technologies rents the ASSURE wearable cardioverter-defibrillator (WCD), a vest-worn device that monitors a patient's heart and shocks it back into rhythm, to people at temporary risk of sudden cardiac arrest, for example in the weeks after a heart attack. It bills Medicare, Medicaid and private insurers for the rental. Billing codes and coverage have existed for over 20 years, and the FDA approved the device in July 2021. For most of that time the market had one product, ZOLL's LifeVest (owned by Asahi Kasei); a second new device (an adhesive-based defibrillator) was cleared by the FDA in May 2025. Fiscal year ends April 30. WHAT HAS HAPPENED. Revenue rose from $27.8M (FY2024) to $59.8M (FY2025) to $95.1M (FY2026), driven by a 58% rise in patients, and the first quarter of FY2027 (ended July 31, 2026) was $31.0M, up about 60%. Gross margin has improved from about 40% to 51% in FY2026 and 56% in the latest quarter, because the cost of serving each patient fell 18%. But spending has grown faster than the profit on that revenue. In FY2026 gross profit rose $24.7M while operating costs rose about $53M, and the operating loss widened from $106M to $135M. In the latest quarter operating costs were again up about $17M against $8.6M more gross profit. The company has never made money, has an accumulated deficit of $652M, and used $81.7M of operating cash plus $34.9M on equipment in FY2026. HOW WE MEASURE IT. We count what the owners actually keep: operating cash flow, less working-capital swings, less stock compensation (a real cost, $33.6M in FY2026), less the equipment spending needed to stand still (about $21M of the $34.9M; the rest we treat as growth spending). On that basis owner earnings were about negative $138M in FY2026 (negative $2.55 per share), negative $106M in FY2025 and negative $90M in FY2024. The losses are getting larger in dollars even as revenue grows. Per-share figures for earlier years look different mainly because the share count changed with the March 2025 IPO and December 2025 offering. WHAT WE CREDIT AND WHAT WE LEAVE OUT. We only give credit for growth that is already secured or that a business has repeated for many years, through a downturn, paid for out of its own cash. Kestra's growth has been strong for three years, but it is funded by selling shares and borrowing, the record covers only three years with no downturn, and it depends on winning patients from a long-standing incumbent while a second competitor has just appeared. So the growth is not counted as secured. What Kestra does have that is real: $245M of cash and investments at July 31, 2026, a proven product with established reimbursement, and improving unit economics. Debt of $75M (a five-year loan closed July 10, 2026 with BioPharma Credit at about the 6% benchmark plus 5.5 points over the base rate, repaying the older $45M Perceptive loan) is deducted; because it costs more than 6% we treat it as about $86M. That leaves net cash of about $159M, or about $2.70 per share on 58.6M shares, before any further losses. THE THREE CASES. Bear case: about $0 per share. The business keeps its current cost base while revenue stalls near the current $124M annual pace, perhaps as the new competitor and ZOLL's response slow patient additions. Burn of about $150M a year uses the net cash in roughly a year, well before the loan's minimum-cash covenant and the 2031 maturity. The business is worth less than nothing on its own (it consumes more cash than it produces); the company owes about $86M and holds about $245M in cash, so net cash of about $159M is spent by continued losses. Shareholders are left with little or nothing after a dilutive raise or lender-driven restructuring. Base case: about $0.20 per share. We hold revenue at today's $124M annual rate and gross margin at 56%, with the operating cost base as it is now (about $220M a year including stock compensation) and about $25M of equipment spending. That yields a business cash drain of roughly $150M in the coming year, which nearly uses up the $159M of net cash. The business is worth roughly negative $150M a year on that path, the company owes about $86M against $245M of cash, and what is left is roughly $10M. We do not credit further growth because none of it meets the standard above, and we do not assume management cuts costs because nothing in the filings commits it to that. Bull case: about $5.20 per share. Revenue keeps growing at a fading pace (50%, 40%, 30%, then tapering to 4% by FY2036, from a base of $95M to about $524M), gross margin reaches 60%, and, the key lever, operating costs stay flat at about $220M a year for five years and then rise only 3% a year. Fleet spending is 12% of revenue. On that path cash burn continues through FY2031 (about $366M in total, needing more capital than the $159M of net cash, funded by the extra $75M of committed loan tranches and share sales), then turns positive and reaches about $44M a year by FY2036, held flat afterward. The business is worth about $145M after including the burn and a tax charge once the large loss carry-forwards run out; adding net cash of about $159M gives about $304M, or $5.20 per share. This is a 90th-percentile outcome because it needs costs to stop growing while revenue triples, which the last two years do not show. WHAT WOULD MAKE THIS WRONG. On the upside, if costs prove to be more flexible than history suggests, value rises quickly; the business already produces gross profit of about $70M a year at the current pace and reimbursement is established. On the downside, ZOLL's decades of physician relationships and the May 2025 competitor could stall patient growth, and payers could reduce rates. The company says cash covers at least 12 months, and the $75M loan carries a minimum-liquidity covenant. Its cash and its ability to raise more, not its earnings, currently carry the value. WHY THE MARGIN-OF-SAFETY PRICE IS WHAT IT IS. The $2.50 margin-of-safety price reflects that today's downside is close to zero, so it is set at or below a large part of today's net cash, and it applies only once cash burn has shown it can fall to about half of today's level (see the business condition).